Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Oct 3.
Published in final edited form as: Cancer Res. 2022 Sep 16;82(18):3406. doi: 10.1158/0008-5472.CAN-22-2399

Retraction: CXCR6 Induces Prostate Cancer Progression by the AKT/Mammalian Target of Rapamycin Signaling Pathway

Jianhua Wang, Yi Lu, Jingchen Wang, Alisa E Koch, Jian Zhang, Russell S Taichman
PMCID: PMC9527645  NIHMSID: NIHMS1838810  PMID: 36111403

This article (1) has been retracted at the request of the authors. In Fig. 3C, the image depicting endothelial control (EC) was also used in Fig. 4C of a separate 2008 paper by the authors (2). In addition, in Fig. 6A, the α-tubulin bands shown in lanes 3 to 5 for the PC3 cells were also used in lanes 1 to 3 for the C4–2B cells. The authors apologize to the scientific community and deeply regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.

A copy of this Retraction Notice was sent to the last known email addresses for 6 of the 6 authors. Two authors (A.E. Koch, R.S. Taichman) agreed to the retraction; 4 authors did not respond.

References

  • 1.Wang J, Lu Y, Wang J, Koch AE, Zhang J, Taichman RS. CXCR6 induces prostate cancer progression by the AKT/Mammalian Target of Rapamycin signaling pathway. Cancer Res 2008;68:10367–77. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 2.Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta K, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008;283:4283–94. [DOI] [PubMed] [Google Scholar]

RESOURCES